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A B S T R A C T
Background
There is significant uncertainty in the treatment of intermediate-stage hepatocellular carcinoma which is defined by the Barcelona
Clinic Liver Cancer (BCLC) as hepatocellular carcinoma stage B with large, multi-nodular, Child-Pugh status A to B, performance
status 0 to 2, and without vascular occlusion or extrahepatic disease.
Objectives
To assess the comparative benefits and harms of different interventions used in the treatment of intermediate-stage hepatocellular
carcinoma (BCLC stage B) through a network meta-analysis and to generate rankings of the available interventions according to their
safety and efficacy. However, we found only one comparison. Therefore, we did not perform the network meta-analysis, and we assessed
the comparative benefits and harms of different interventions versus each other, or versus placebo, sham, or no intervention (supportive
treatment only) using standard Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded,
World Health Organization International Clinical Trials Registry Platform, and randomised clinical trials registers to September 2016
to identify randomised clinical trials on hepatocellular carcinoma.
Selection criteria
We included only randomised clinical trials, irrespective of language, blinding, or publication status, in participants with intermediate-
stage hepatocellular carcinoma, irrespective of the presence of cirrhosis, size, or number of the tumours (provided they met the
criteria of intermediate-stage hepatocellular carcinoma), of presence or absence of portal hypertension, of aetiology of hepatocellular
carcinoma, and of the future remnant liver volume. We excluded trials which included participants who had previously undergone liver
transplantation. We considered any of the various interventions compared with each other or with no active intervention (supportive
treatment only). We excluded trials which compared variations of the same intervention: for example, different methods of performing
transarterial chemoembolisation.
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Data collection and analysis
Weused standardmethodological procedures expected by Cochrane.We calculated the hazard ratio (HR) with 95% confidence intervals
(CI) using both fixed-effect and random-effects models based on available-participant analysis with Review Manager. We assessed risk
of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis using Stata, and assessed the quality of
the evidence using GRADE.
Main results
Three randomised clinical trials, including 430 participants, met the inclusion criteria for this review; however, data from two trials
with 412 participants could be included in only one primary outcome (i.e. mortality). All three trials were at high risk of bias. All three
trials included supportive care as cointervention. The comparisons included in the two trials reporting on mortality were: systemic
chemotherapy with sorafenib versus no active intervention; and transarterial chemoembolisation plus systemic chemotherapy with
sorafenib versus transarterial chemoembolisation alone. The trials did not report the duration of follow-up; however, it appeared that
the participants were followed up for a period of about 18 to 30 months. The majority of the participants in the trials had cirrhotic
livers. The trials included participants with intermediate-stage hepatocellular carcinoma arising from viral and non-viral aetiologies. The
trials did not report the portal hypertension status of the participants. The mortality was 50% to 70% over a median follow-up period
of 18 to 30 months. There was no evidence of difference in mortality at maximal follow-up between systemic chemotherapy versus no
chemotherapy (hazard ratio 0.85, 95% CI 0.60 to 1.18; participants = 412; studies = 2; I2 = 0%; very low quality evidence). A subgroup
analysis performed by stratifying the analysis by the presence or absence of transarterial chemoembolisation as cointervention did not
alter the results. None of the trials reported on serious adverse events other than mortality, health-related quality of life, recurrence of
hepatocellular carcinoma, or length of hospital stay. One of the trials providing data was funded by the pharmaceutical industry, the
other did not report the source of funding, and the trial with no data for the review was also funded by the pharmaceutical industry.
We found two ongoing trials.
Authors’ conclusions
Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would
benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention
(very low quality evidence). We need high-quality randomised clinical trials designed to measure differences in clinically important
outcomes (e.g. all-cause mortality or health-related quality of life).
P L A I N L A N G U A G E S U M M A R Y
Treatment of intermediate-stage primary liver cancer (hepatocellular carcinoma)
Background
Hepatocellular carcinoma (primary liver cancer) arises from the liver cells and is distinct from secondary liver cancer, arising from other
parts of the body and spreading to the liver. Hepatocellular carcinoma can be classified in many ways. One classification is by Barcelona
Clinic Liver Cancer (BCLC) group stage which classifies the cancer based on how long the person is expected to live (life expectancy).
This classification is broadly based on the size of the cancer, number of cancers in the liver, how well the liver works, and whether one’s
activities are affected by the cancer. People with intermediate-stage hepatocellular carcinoma have large, multiple cancers, but they
do not have full-blown liver failure. Cancer is confined to the liver, and there is no restriction of daily activities. There is significant
uncertainty in the treatment of people with intermediate-stage hepatocellular carcinoma. We sought to resolve this uncertainty by
searching for existing studies on the topic. We included all randomised clinical trials (well-designed clinical trials where people are
randomly put into one of two or more treatment groups) whose results were reported to September 2016. We included only trials in
which participants with intermediate-stage hepatocellular carcinoma had not undergone liver transplantation previously. Apart from
using standard Cochrane methods which allow comparison of only two treatments at a time (direct comparison), we planned to use
an advanced method which allows comparison of the many different treatments that are individually compared in the trials (network
meta-analysis). However, because there was only one comparison, we could only use standard Cochrane methodology.
Study characteristics
Only three trials with 430 participants met our inclusion criteria; however, two of the trials (412 participants) only reported death
and no other measures of how well the treatments worked. All three trials included supportive care (treatment to prevent, control, or
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relieve complications and side effects and improve comfort and quality of life) as a co-intervention. The trials assessed transarterial
chemoembolisation (where anti-cancer drugs block the blood supply and treat the cancer through the vessels supplying the cancer),
chemotherapy using sorafenib (a drug which blocks cancer growth), or a combination of transarterial chemoembolisation and sorafenib.
It appeared that the trials followed participants for about 18 to 30 months from the initiation of treatment.
Two trials were funded by the pharmaceutical industry; one trial did not report the source of funding.
Key results
Over 18 to 30 months, 50% to 75% of participants died. There was no evidence of any difference between the people who received
chemotherapy and those who did not receive chemotherapy. None of the trials reported complications, health-related quality of life (a
measure of a person’s satisfaction with their life and health), cancer recurrence, or length of hospital stay. Overall, there is currently no
evidence for benefit of any active treatment in addition to supportive treatment for intermediate-stage hepatocellular carcinoma. There
is significant uncertainty on this and further high-quality randomised clinical trials are required.
Quality of evidence
The overall quality of evidence was low or very low and all the trials were at high risk of bias, which means that there is possibility of
making the wrong conclusions, overestimating benefits, or underestimating harms of one treatment or the other because of the way
that the trials were conducted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chemotherapy versus no chemotherapy for intermediate-stage hepatocellular carcinoma
Patient or population: people with intermediate-stage hepatocellular carcinoma
Settings: secondary or tert iary care
Intervention: systemic chemotherapy
Control: no systemic chemotherapy
a Cointervention: t ransarterial chemoembolisat ion in both groups in 1 trial
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No systemic chemotherapy
a
Systemic chemotherapya
M ortality (at maximal fol-
low-up) - chemotherapy
versus no chemotherapy
Median follow-up in trials:
12 to 24 months
500 per 1000 445 per 1000
(340 to 559)
HR 0.85
(0.60 to 1.18)
412
(2 trials)
⊕⊕©©
Very low1,2,3
Short- term and medium-
term mortality
None of the trials reported short-term or medium-term mortality
Adverse events None of the trials reported adverse events.
Quality of life None of the trials reported quality of lif e at any t ime point
Disease recurrence None of the trials reported disease recurrence.
Length of hospital stay None of the trials reported length of hospital stay.
* The basis for the assumed risk was the control group proport ion in the studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; HR: hazard rat io.4
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level because of within-study risk of bias: the trials were at high risk of bias.
2 Downgraded one level because of imprecision: the sample size was small.
3 Downgraded one level because of imprecision: the conf idence intervals overlapped no ef fect and clinically signif icant ef fect.
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B A C K G R O U N D
Description of the condition
Hepatocellular carcinoma is the major form of primary liver can-
cer (Bosetti 2014; NCBI 2014). An estimated 782,000 people de-
velop hepatocellular carcinoma and 746,000 people die because
of primary liver cancer each year worldwide (IARC 2014a). It is
the sixth most common cancer overall with an age standardised
incidence rate of 10.1 per 100,000 population per year (IARC
2014b). It is the second most common cause of death from can-
cer worldwide (IARC 2014a). It is more common in men than
women (IARC 2014a). There is global variation in the incidence
and mortality related to primary liver cancer. Approximately half
of all primary liver cancers occur in China (395,000 people per
year). Northern Europe has the lowest incidence of primary liver
cancer (IARC 2014a). There is an increase in the incidence of
hepatocellular carcinoma in many countries (Davila 2004; Jepsen
2007; Pocobelli 2008; Taura 2009; Von Hahn 2011;Witjes 2012;
Bosetti 2014; Ladep 2014). This increase is attributed to hepatitis
C virus infection (Davila 2004; Taura 2009). Alcohol-related liver
disease, hepatitis B virus infection, and hepatitis C virus infection
are major risk factors for hepatocellular carcinoma (Davila 2004;
Bosetti 2014). Other risk factors include aflatoxin in foods (toxins
produced by Aspergillus fungus), smoking, being overweight, di-
abetes, and non-alcohol related steatohepatitis (Lee 2009; Polesel
2009; Starley 2010; Chen 2012; Liu 2012; Bosetti 2014; Turati
2014). The incidence of hepatocellular carcinoma is higher in
people with a family history of hepatocellular carcinoma, and
lower in people with high intake of vegetables and coffee (Turati
2012; Sang 2013; Bosetti 2014; Yang 2014). The association be-
tween oral contraceptives and hepatocellular carcinoma is unclear
and there is currently no evidence of an increased risk between
women using oral contraceptives and women who do not use oral
contraceptive based on one meta-analysis of observational studies
(Maheshwari 2007). Hepatocellular carcinoma usually develops
in cirrhotic livers although it may also develop in non-cirrhotic
livers (Arnaoutakis 2014; Gaddikeri 2014). Hepatocellular car-
cinomas that develop in non-cirrhotic livers are usually solitary
but larger compared to hepatocellular carcinomas that develop in
cirrhotic livers (Gaddikeri 2014). The role of routine screening
for hepatocellular carcinomas in people with chronic liver disease
is controversial with one systematic review concluding that there
was no evidence of benefit of routine screening for people with
hepatocellular carcinoma (Kansagara 2014).
Description of the intervention
Several classifications of hepatocellular carcinoma have been pro-
posed. This includes clinical staging classifications, histopatho-
logical classifications, and molecular classifications (Wu 1996;
Henderson 2003; Van Deusen 2005; Cillo 2006; Nanashima
2006; VanMalenstein 2011). Of these, the Barcelona Clinic Liver
Cancer (BCLC) staging system (Llovet 1999; Llovet 2003), and
the Milan criteria (Mazzaferro 1996), are important classification
systems that determine the management of hepatocellular carci-
noma. Appendix 1 and Appendix 2 show these classification sys-
tems in detail. Stage 0 (very early hepatocellular carcinoma) and
stage A (early hepatocellular carcinoma) of BCLC staging corre-
spond approximately to tumours falling within Milan criteria al-
though Stage A of the BCLC staging system includes a single tu-
mour of any size while a single tumour should be less than 5 cm
to fall within Milan criteria. This review examines the treatment
options for people with intermediate-stage hepatocellular carci-
noma (large multi-nodular tumours with no evidence of vascular
invasion or extrahepatic spread and performance status 0). A sepa-
rate review covers the treatment options for people with very-early
hepatocellular carcinoma (single nodule less than 2 cm in diame-
ter, Child-Pugh A cirrhosis, and performance status 0) and early
hepatocellular carcinoma (single tumour or two or three lesions
less than 3 cm in maximum diameter with no evidence of vascular
invasion or extrahepatic spread, Child-Pugh A or B cirrhosis, and
performance status 0) (Majumdar 2017).
Various treatments are aimed at intermediate-stage hepatocellu-
lar carcinoma. These can be broadly classified as surgical, abla-
tive techniques, radiotherapy, transcatheter arterial embolisation
(TAE), and transcatheter arterial chemoembolisation (TACE).
The surgical management of hepatocellular carcinoma is in the
formof liver resection and liver transplantation (Bruix 2011; EASL
2012; Asham 2013). Liver resection is performed to ensure that all
the tumours are removed with adequate remnant liver to carry out
the normal functions of the liver (Asham 2013). Liver resection is
usually performed by open technique although laparoscopic (key
hole) liver resection can be performed in a selection of people
(Nguyen 2009). Complications related to liver resection include
mortality, liver failure, bile leak, bleeding, liver abscess, abdominal
abscess, wound infection, and general complications such as heart
failure and renal failure (Nguyen 2009; Xiong 2012). Liver trans-
plantation involves removal of the diseased liver and transplant-
ing a liver graft from another donor (usually a cadaveric donor)
(SRTR 2012; NHSBT 2014). Living donor liver transplantation
is associated with increased complications and increased incidence
of retransplantation and constitutes only a small proportion of
the global liver transplantation (Wan 2014). The complications
of liver transplantation include mortality, graft failure, graft rejec-
tion, biliary stricture, hepatic artery thrombosis, and wound in-
fections (Gurusamy 2014; Wan 2014).
Ablation is usually in the form of radiofrequency ablation (Bruix
2011; EASL 2012; Asham 2013), but other modalities exist, such
as chemical ablation using percutaneous alcohol or acetic acid in-
jections, ablations such as microwave ablation, laser (light amplifi-
cation by stimulated emission of radiation) ablation, cryoablation,
high-intensity focused ultrasound (HIFU), and irreversible elec-
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troporation (Head 2004; Germani 2010; Sindram 2010; Chan
2013a). Complications related to ablation include mortality, liver
failure, bleeding, liver abscess, bile duct injuries, and tumour dis-
semination through the needle tract (’seeding’) or into the peri-
toneum (Chan 2013a; McDermott 2013).
Radiotherapy is usually in the form of stereotactic body radio-
therapy and radioembolisation. Stereotactic body radiotherapy in-
volves delivering external radiotherapy in large divided doses (usu-
ally five or fewer doses) with the radiation focused on the lesions
(Kollar 2014). Radioembolisation involves intra-arterial injection
of small microspheres (25 mm to 35 mm) containing the radionu-
clide Yttrium (Forner 2014). Major complications of radiother-
apy include worsening of cirrhosis and liver toxicity, which may
manifest as liver failure (Forner 2014; Kollar 2014).
TAE involves embolisation of the hepatic artery without using
any chemotherapeutic agents, while TACE involves injection of
a chemotherapeutic agent prior to embolisation of the hepatic
artery (Pleguezuelo 2008). TACE can also be performed using
drug-eluting beads (Forner 2014; Hoffmann 2014). Both TAE
and TACE are unstandardised procedures, with varying chemo-
therapeutic and embolising agents used and different protocols of
retreatment following the index embolisation (Tsochatzis 2014).
Major complications of TAE and TACE include mortality, liver
failure, liver and splenic abscesses, acute cholecystitis, damage to
the bile ducts, renal failure, and severe upper gastrointestinal bleed-
ing (Pleguezuelo 2008).
How the intervention might work
Liver resection and liver transplantation work by removing the
cancer. Chemical ablations using alcohol injections and acetic acid
injections destroy the cancer tissue (Sindram 2010). Thermal ab-
lations cause destruction of cancer tissue by heat or cold (Sindram
2010). TAE and TACE cause ischaemia to the tumour thereby
causing tumour necrosis (Pleguezuelo 2008). TACE combines the
effect of chemotherapy agents, which inhibit the tumour in addi-
tion to the effect of ischaemia on the tumour, although the main
effect of TACE may be due to the ischaemia rather than the che-
motherapy delivered via the artery (Pleguezuelo 2008).
Why it is important to do this review
The current guidelines on the management of hepatocellular car-
cinoma by the European Association for the Study of the Liver
and the American Association for the Study of Liver Diseases rec-
ommend TACE for people with intermediate-stage hepatocellular
carcinoma (Bruix 2011; EASL 2012). In this situation, TACE is
considered palliative (Bruix 2011; EASL 2012) and there is no
evidence that TACE increases survival or health-related quality
of life (Oliveri 2011). Some researchers advocate liver transplan-
tation for selected people with intermediate-stage hepatocellular
carcinoma, while other researchers do not (Germani 2011; Prasad
2011). However, it must be noted that people with hepatocellular
carcinoma have to compete with other people waiting for liver
transplantation. In 2012, pretransplant deaths occurred at the rate
of 5.8 deaths per 100 waiting-list years in the US (SRTR 2012),
and in the year to the end of March 2014, 12% of people on the
liver transplantation waiting list in the UK died or became too un-
well to have a transplant (NHSBT 2014). This indicates an organ
shortage necessitating an organ allocation policy. The Milan cri-
teria are now used for organ transplant allocation in many coun-
tries. In the US, eligible people with hepatocellular carcinoma are
given exceptional status so that they do not remain on the waiting
list too long, as delay in transplantation will increase the chance
of tumour progression or dissemination (OPTN 2014). People
with hepatocellular carcinoma must meet the Milan criteria but,
in addition, need to have a minimum tumour size of 2 cm if they
have a single tumour and a minimum tumour size of 1 cm each
if they have two or three lesions to be considered eligible for ex-
ceptional status (OPTN 2014). However, expanding the existing
criteria for liver transplantation for people with intermediate-stage
hepatocellular carcinoma should be carefully assessed and should
be evidence-based because of the impact that this might have on
other people requiring liver transplantation. There have also been
calls to recommend liver resection for people with intermediate-
stage hepatocellular carcinoma (Guglielmi 2014). Thus, the opti-
mal management of people with intermediate-stage hepatocellu-
lar carcinoma is not known. Network meta-analysis allows com-
bination of the direct evidence and indirect evidence and allows
ranking of different interventions in terms of the different out-
comes (Salanti 2011; Salanti 2012). There has been no network
meta-analysis on the different interventions for intermediate-stage
hepatocellular carcinoma. This systematic review and attempted
network meta-analysis attempts to provide the best level of evi-
dence for the role of different treatment options for people with
intermediate-stage hepatocellular carcinoma.
O B J E C T I V E S
To assess the comparative benefits and harms of different inter-
ventions used in the treatment of intermediate-stage hepatocellu-
lar carcinoma (BCLC stage B) through a network meta-analysis
and to generate rankings of the available interventions according
to their safety and efficacy. However, there was only one com-
parison included for this review. Therefore, we did not perform
the network meta-analysis, and we assessed the comparative bene-
fits and harms of different interventions using standard Cochrane
methodology.Whenmore trials become available, we will attempt
to conduct network meta-analysis in order to generate rankings of
the available interventions according to their safety and efficacy.
This is why we retain the planned methodology for network meta-
analysis in our Appendix 3. Once data appear allowing for the
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conduct of network meta-analysis, this Appendix 3 will be moved
back into the Methods section.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials, irrespective of lan-
guage, publication status, or date of publication. We excluded
studies of other design because of the risk of bias in such studies.
We are all aware that such exclusions make us focus muchmore on
potential benefits and not fully assess the risks of serious adverse
events as well as risks of adverse events.
Types of participants
We included participants with intermediate-stage hepatocellular
carcinoma (BCLC stage B) irrespective of the presence of cirrhosis,
size and number of the tumours (provided they met the criteria of
intermediate-stage hepatocellular carcinoma), presence or absence
of portal hypertension, aetiology of hepatocellular carcinoma, and
the future remnant liver volume.We excluded randomised clinical
trials in which participants had undergone liver transplantation
previously.
Types of interventions
We planned to include any of the following interventions that
are possible treatments for intermediate-stage hepatocellular car-
cinoma either alone or in combination tested versus each other, or
versus placebo or sham, or no intervention (supportive care):
• liver resection;
• liver transplantation;
• radiofrequency ablation;
• microwave ablation;
• other ablations (laser ablation, cryoablation, HIFU,
irreversible electroporation);
• alcohol injection;
• acetic acid injection;
• radiotherapy (stereotactic body radiotherapy or
radioembolisation);
• systemic chemotherapy;
• TAE;
• TACE;
• supportive care.
The above list is not exhaustive. If we identified interventions that
we were not aware of, we would have considered them as eligible
and would have included them in the review, if they were used
primarily for the treatment of hepatocellular carcinoma. If liver
resection or liver transplantation were combined with ablation,
TAE, or TACE, we planned to categorise the intervention as liver
resection or liver transplantation. This is because liver resection
and liver transplantation are the major components in such inter-
ventions, with ablation, TAE, or TACE playing exclusively a sup-
portive role to liver resection or liver transplantation. However, we
planned to exclude such interventions from a sensitivity analysis
(see Sensitivity analysis). If we found a sufficient number of trials
on one or more of the other methods of ablation (laser ablation,
cryoablation, HIFU, irreversible electroporation), we planned to
consider the specific method of ablation with sufficient trials as a
separate intervention.
Types of outcome measures
We planned to assess the comparative benefits and harms of avail-
able interventions aimed at treating peoplewith intermediate-stage
hepatocellular carcinoma for the following outcomes.
Primary outcomes
• Mortality at maximal follow-up (time to death).
• Mortality:
◦ short-term mortality (up to one year);
◦ medium-term mortality (one to five years).
• Adverse events (within three months of cessation of
treatment). Depending on the availability of data, we planned to
attempt to classify adverse events as serious and non-serious. We
defined a non-serious adverse event as any untoward medical
occurrence not necessarily having a causal relationship with the
treatment but resulting in a dose reduction or discontinuation of
treatment (any time after commencement of treatment)
(ICH-GCP 1997). We defined a serious adverse event as any
event that would increase mortality; was life threatening;
required hospitalisation; resulted in persistent or significant
disability; was a congenital anomaly/birth defect; or any
important medical event that might jeopardise the person or
require intervention to prevent it. We used the definition used by
study authors for non-serious and serious adverse events:
◦ proportion of participants with serious adverse events;
◦ number of serious adverse events;
◦ proportion of participants with any type of adverse
event;
◦ number of any type of adverse event.
• Quality of life as defined in the included trials using a
validated scale such as EQ-5D or 36-item Short Form (SF-36)
(EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years);
◦ long-term (beyond five years).
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We considered long-term quality of life more important than
short-term or medium-term quality of life, although short-term or
medium-term quality of life are also important primary outcomes.
Secondary outcomes
• Disease recurrence (maximum follow-up):
◦ proportion of participants with hepatocellular
carcinoma recurrence (includes recurrence in the liver and
metastatic disease);
◦ proportion of participants with local recurrence
(recurrence in the liver);
◦ time to hepatocellular carcinoma recurrence;
◦ time to local recurrence.
• Length of hospital stay for the intervention and
intervention-related complications. If intervention was
performed in two or more sessions, we planned to calculate the
total length of hospital stay for all the sessions. Similarly, we
planned to include length of hospital stay for readmissions
within 30 days of intervention because of intervention-related
complications in the length of hospital stay.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL; 2016, Issue 8), MEDLINE (OvidSP), Embase
(OvidSP), and Science Citation Index Expanded (Web of Knowl-
edge) (Royle 2003) from inception to 30 September 2016 for
randomised clinical trials comparing two or more of the above
interventions. We searched for all possible comparisons formed
by the interventions of interest. To identify further ongoing or
completed trials, we also searched the World Health Organiza-
tion International Clinical Trials Registry Platform search portal
(apps.who.int/trialsearch/), which searches various trial registers,
including ISRCTN and ClinicalTrials.gov. Appendix 4 shows the
search strategies that we used and the time spans of the searches.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane Reviews on hepatocellular carcinoma to identify addi-
tional trials for inclusion.
Data collection and analysis
Selection of studies
Review authors (KG, AM, or DR between them) independently
identified the trials for inclusion by screening the titles and ab-
stracts. We sought full-text articles for any references that at least
one of the review authors identified for potential inclusion. We
selected trials for inclusion based on the full-text articles. We have
listed the excluded full-text references with reasons for their exclu-
sion in the Characteristics of excluded studies table. We listed any
ongoing trials identified primarily through the search of the clini-
cal trial registers for further follow-up (Characteristics of ongoing
studies table). We resolve discrepancies through discussion.
Data extraction and management
Two review authors (KG and AM or DR) independently extract
the following data.
• Outcome data (for each outcome and for each intervention
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of people with or without cirrhosis,
tumour size, number of tumours, presence of portal
hypertension, aetiology of hepatocellular carcinoma, and
adjuvant treatments such as immunotherapy;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain the data separately for people
with and without cirrhosis, presence compared to absence of por-
tal hypertension, and viral compared to non-viral aetiology. We
sought unclear or missing information by attempting to contact-
ing the trial authors, but we did not obtain any additional infor-
mation. If there was any doubt whether trials shared the same par-
ticipants, completely or partially (by identifying common authors
and centres), we planned to contact the trial authors to clarify
whether the trial report was duplicated. We resolved any differ-
ences in opinion through discussion.
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Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and described
in the Cochrane Hepato-Biliary Group Module (Gluud 2016) to
assess the risk of bias in included studies. Specifically, we assessed
the risk of bias in included trials for the following domains using
the methods below (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We only included such studies for assessment of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We only
included such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: at least medium-term or long-term mortality and
treatment-related adverse events. If the original trial protocol was
available, the outcomes should have been those called for in that
protocol. If the trial protocol was obtained from a trial registry
(e.g. www.clinicaltrials.gov), the outcomes sought should have
been those enumerated in the original protocol if the trial
protocol was registered before or at the time that the trial was
begun. If the trial protocol was registered after the trial was
begun, those outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
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• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control) that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. inappropriate control or dose or
administration of control).
We considered a trial to be at low risk of bias if we assessed the trial
as at low risk of bias across all domains. Otherwise, we considered
trials at unclear risk of bias or at high risk of bias regarding one or
more domains as at high risk of bias. Since blinding of healthcare
providers is impossible for all the comparisons and blinding of
the participants is unlikely for comparisons involving surgery, we
planned to assess the potential influence of lack of blinding on the
outcomes carefully. We planned to classify the trials to be at high
risk of bias for all the outcomes other than mortality because of
the potential influence of lack of blinding on the other outcomes.
Measures of treatment effect
For dichotomous variables (e.g. short-term mortality, medium-
term mortality, and proportion of participants with adverse
events), we planned to calculate the odds ratio with 95% confi-
dence intervals (CI). For continuous variables (e.g. hospital stay
and quality of life reported on the same scale), we planned to cal-
culate the mean difference with 95% CI. We planned to use stan-
dardised mean difference values with 95% CI for quality of life
if included trials used different scales. For count outcomes (e.g.
number of adverse events), we planned to calculate the rate ratio
with 95% CI. For time-to-event data (e.g. mortality at maximal
follow-up), we calculated hazard ratio (HR) with 95% CI.
Unit of analysis issues
The unit of analysis was the person with intermediate-stage hepa-
tocellular carcinoma according to the intervention group to which
they were randomly assigned.
Cluster randomised clinical trials
We found no cluster randomised clinical trials. However, if we
found them, we planned to include them provided that the effect
estimate adjusted for cluster correlation was available.
Cross-over randomised clinical trials
We found no cross-over randomised clinical trials. If we identified
any, we planned to only include the outcome results after the
period of first intervention since the first intervention may have a
permanent impact on the outcome (i.e. have a residual effect).
Trials with multiple treatment groups
We planned to collect data for all trial treatment groups that met
the inclusion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data available to us (e.g. a
trial may have reported only per-protocol analysis results). As such
’per-protocol’ analyses may be biased, we planned to conduct best-
worst case scenario analyses (good outcome in intervention group
and bad outcome in control group) and worst-best case scenario
analyses (bad outcome in intervention group and good outcome
in control group) as sensitivity analyses whenever possible.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the data were likely to be normally distributed, we planned to
use the median for meta-analysis when the mean was not avail-
able. If it was not possible to calculate the standard deviation from
the P value or the confidence intervals, we planned to impute the
standard deviation using the largest standard deviation in other
trials for that outcome. This form of imputation may decrease the
weight of the study for calculation of mean differences and may
bias the effect estimate to no effect for calculation of standardised
mean differences (Higgins 2011).
Assessment of heterogeneity
We planned to assess clinical and methodological heterogeneity
by carefully examining the characteristics and design of included
trials. We planned to assess the presence of clinical heterogeneity
by comparing effect estimates in people with and without cirrho-
sis, presence or absence of portal hypertension, aetiology of hepa-
tocellular carcinoma, and adjuvant treatment with immunother-
apy. Different study designs and risk of bias may contribute to
methodological heterogeneity.
We used the I2 test and Chi2 test for heterogeneity, and over-
lapping of CIs to assess heterogeneity. If we identified substantial
heterogeneity, clinical, methodological, or statistical, we explored
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and address heterogeneity in a subgroup analysis (see Subgroup
analysis and investigation of heterogeneity).
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997;Macaskill 2001). In
the presence of heterogeneity that could be explained by subgroup
analysis, we planned to produce a funnel plot for each subgroup
in the presence of the adequate number of trials. We planned to
use the linear regression approach described by Egger 1997 to
determine funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We performed the meta-analyses according to the recommenda-
tions of The Cochrane Collaboration (Higgins 2011), using the
software package Review Manager 5 (RevMan 2014). We used
a random-effects model (DerSimonian 1986) and a fixed-effect
model (DeMets 1987). In the case of a discrepancy between the
two models, we planned to report both results. However, since
there was no discrepancy, we have reported only the results from
the fixed-effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 5.
We performedTrial Sequential Analysis to control the risks of ran-
dom errors (Wetterslev 2008; Thorlund 2011; TSA 2011) when
there were at least two trials included in the outcome. We used an
alpha error as per guidance of Jakobsen 2014, power of 90% (beta
error of 10%), a relative risk reduction of 20%, a control group
proportion observed in the trials, and the heterogeneity observed
in themeta-analysis. Since the only outcomewasmortality atmax-
imal follow-up, a time-to-event outcome, we performed the Trial
Sequential Analysis using Stata/SE 14.2 using methods suggested
by Miladinovic 2013.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials at low risk of bias compared to trials at high risk of
bias.
• People with and without cirrhosis.
• Presence compared to absence of portal hypertension.
• Viral compared to non-viral aetiology.
• Use of immunotherapy or antiviral therapy or other
treatments as adjuvant therapy compared to no use.
We planned to use the chi2 test for subgroup differences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
reanalyse the results using the best-worst case scenario and worst-
best case scenario analyses as sensitivity analyseswhenever possible.
In addition, we planned to exclude trials in which liver resection
or liver transplantation were combined with ablation, TAE, or
TACE.
Presentation of results and GRADE assessments
If trials reported on all our predefined outcomes, we planned to
report all of them in a ’Summary of findings’ table format, down-
grading the quality of evidence for risk of bias, inconsistency, indi-
rectness, imprecision, and publication bias using GRADE (Guyatt
2011).
R E S U L T S
Description of studies
Results of the search
We identified 4048 references through electronic searches ofCEN-
TRAL (N = 264), MEDLINE (N = 1723), Embase (N = 451),
Science Citation Index Expanded (N = 1443), World Health Or-
ganization International Clinical Trials Registry Platform (N =
137), and ClinicalTrials.gov (N = 30). After the removal of 680
duplicates, we obtained 3368 references. We then excluded 3294
clearly irrelevant references through screening titles and reading
abstracts.We retrieved 74 references for further assessment.No ref-
erences were identified through scanning reference lists of the iden-
tified randomised trials.We excluded 63 references (62 studies) for
the reasons listed in the Characteristics of excluded studies table;
three references (two trials) were ongoing trials with no interim
data (Seinstra 2012; NCT02854839; Characteristics of ongoing
studies table). In total, eight references (three trials) met the inclu-
sion criteria (Bruix 2012; de Stefano 2015; Lencioni 2016). The
study flow diagram summarises the reference flow (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We included three trials with 430 participants in this review (Bruix
2012; de Stefano 2015; Lencioni 2016). Two of the trials (412
participants) provided data for only one outcome of this review,
that is, mortality (Bruix 2012; Lencioni 2016). All trials included
supportive care as a cointervention. The comparisons included in
the trials were:
• systemic chemotherapy with sorafenib versus no active
intervention (one trial with 105 participants; Bruix 2012);
• radiofrequency ablation plus systemic chemotherapy with
sorafenib versus radiofrequency ablation (one trial with 18
participants; de Stefano 2015 - an ongoing trial and the interim
report did not contain any outcomes of interest);
• transarterial chemoembolisation plus systemic
chemotherapy with sorafenib versus transarterial
chemoembolisation (one trial with 307 participants; Lencioni
2016).
The mean age in the trials that reported this information was 64
years (Lencioni 2016) and 69 years (Bruix 2012). The proportion
of females in the trials that reported this information was 15%
(46/307 participants) (Lencioni 2016) and 15.2% (16/105 par-
ticipants) (Bruix 2012). The proportion of participants with cir-
rhosis in the trial that reported this information was 87.9% (270/
307 participants) (Lencioni 2016). None of the trials reported
whether participants had portal hypertension. The proportion of
participants with viral aetiology in the trials that reported this
information was 37.1% (39/105 participants) (Bruix 2012) and
64.2% (197/307 participants) (Lencioni 2016). None of the trials
reported use of immunotherapy or antiviral therapies as adjuvant
therapy.
Follow-up period: the three trials did not report the duration of
follow-up. However, the Kaplan-Meier curves from the two trials
that provided data for this review suggested that participants were
followed up for a period of about 18 to 30 months (Bruix 2012;
Lencioni 2016).
Source of funding: two trials were funded by the pharmaceutical
industry (Bruix 2012; de Stefano 2015); one trial did not report
the source of funding (Lencioni 2016).
Excluded studies
We excluded 63 references for the reasons given in the
Characteristics of excluded studies table.
Risk of bias in included studies
The risk of bias is summarised in Figure 2 and Figure 3. None of
the trials were at low risk of bias for all domains; hence, all trials
were at high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
14Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
One trial reported the sequence generation adequately and was
at low risk of bias in this domain (Bruix 2012). The remaining
trials were at unclear risk of bias in this domain (de Stefano 2015;
Lencioni 2016). One trial reported allocation concealment ade-
quately, and was at low risk of bias in this domain (Bruix 2012).
The remaining trials were at unclear risk of bias in this domain (de
Stefano 2015; Lencioni 2016). Overall, one trial was at low risk
of selection bias (Bruix 2012); the remaining trials were at unclear
risk of bias (de Stefano 2015; Lencioni 2016).
Blinding
Two trials achieved blinding of participants, healthcare providers,
and outcome assessors (Bruix 2012; Lencioni 2016); these two
trials were at low risk of performance and detection biases. In one
trial, there was no blinding of participants, healthcare providers,
or outcome assessors (de Stefano 2015); this trial was at high risk
of performance and detection biases.
Incomplete outcome data
There were no post-randomisation dropouts in two trials (Bruix
2012; Lencioni 2016); these two trials were at low risk of attrition
bias. The remaining trial did not report whether there were any
post-randomisation dropouts (de Stefano 2015); this trial was at
unclear risk of attrition bias.
Selective reporting
Published protocols of the trials were not available for any of the
trials. The trials did not report either mortality or adverse events,
or both; therefore, all three trials were at high risk of reporting bias
(Bruix 2012; de Stefano 2015; Lencioni 2016).
Other potential sources of bias
Two trials were funded by the pharmaceutical industry and were
at high risk of ’for-profit bias’ (Bruix 2012; de Stefano 2015). One
trial did not report the source of funding and was at unclear risk
of ’for-profit bias’ (Lencioni 2016). There was no other bias in any
of the trials.
Effects of interventions
See: Summary of findings for the main comparison
Chemotherapy versus no chemotherapy for intermediate-stage
hepatocellular carcinoma
Mortality (at maximal follow-up)
Two trials (412 participants) reported mortality at maximal fol-
low-up (Bruix 2012; Lencioni 2016). Mortality was 50% to 75%
over a median follow-up period of 12 to 24 months in the two
trials (Bruix 2012; Lencioni 2016). We performed a meta-analysis
assuming that the presence or absence of transarterial embolisa-
tion did not influence the effect of systemic chemotherapy. There
was no evidence of difference in mortality at maximal follow-up
between systemic chemotherapy versus no chemotherapy (hazard
ratio 0.85, 95% CI 0.60 to 1.18; participants = 412; studies = 2; I
2 = 0; very low quality evidence; Analysis 1.1). The interpretation
of results did not change by using a random-effects model. A sub-
group analysis stratified by the presence or absence of transarterial
chemoembolisation as cointervention did not alter the results.
Trial Sequential Analysis: based on an alpha error of 5%, power
of 90% (beta error of 10%), a relative risk reduction of 20%, the
control group proportion of 50%, and observed heterogeneity of
0%, the required information size was 2011. As shown in Figure
4, the z-curve (blue line) did not cross any of the boundaries
indicating a high risk of random error.
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Figure 4. Trial Sequential Analysis of mortality at maximal follow-up: based on an alpha error of 2.5%,
power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, the control group proportion (Pc) of
50%, and observed heterogeneity (0%), the a priori information size (APIS) was 2011. As shown in the figure,
the cumulative Z-curve (blue line) do not cross any of trial sequential monitoring boundaries (red lines). They
do not cross the conventional alpha boundary of 2.5% (green line) either.
Short-term mortality (up to one year)
None of the trials reported proportion of people dead in the short-
term (up to one year).
Medium-term mortality (one to five years)
None of the trials reported proportion of people dead in the
medium-term (one to five years).
Serious adverse events
None of the trials reported serious adverse events.
Adverse events
None of the trials reported the proportion or number of adverse
events.
Quality of life
None of the trials reported quality of life at any time point.
Disease recurrence
None of the trials reported recurrence of hepatocellular carcinoma.
Length of hospital stay
None of the trials reported length of hospital stay.
Reporting bias
We did not explore reporting bias because of the sparse data.
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Subgroup analysis
Wedidnot performany subgroup analyses other than stratification
by presence or absence of transarterial chemoembolisation as a
cointervention because of the sparse data.
Sensitivity analysis
Since none of the trials reported any binary outcomes, we did not
perform any sensitivity analyses. Since none of the trials reported
length of hospital stay, the issue of imputing standard deviation
did not arise.
Quality of evidence
The overall quality of the evidence was very low for the reported
outcome of mortality. All the trials were at high risk of bias (result-
ing in downgrading it one level). There was no evidence of incon-
sistency in the only outcome. There was no issue of indirectness,
since the outcome reported was a clinical outcome and only direct
comparisons were used. The sample size was small (downgraded
by one level) and the confidence intervals overlapped no effect and
clinically significant effect (downgraded one level). We did not
explore publication bias because of the too few trials included in
this review (Summary of findings for the main comparison).
D I S C U S S I O N
Summary of main results
We included two trials (412 participants) in one outcome for this
review (Bruix 2012; Lencioni 2016). Because of the sparse data,
we did not perform a network meta-analysis (as there were no
comparisons in which it was possible to obtain direct and indirect
estimates, which would have allowed the assessment of inconsis-
tency) and we used Frequentist methods for performing the direct
comparisons. Of the two trials which provided data for this review,
one trial compared active interventions (systemic chemotherapy;
Bruix 2012) in addition to supportive treatments versus support-
ive treatments only. One trial compared two active interventions
(transarterial chemoembolisation with and without systemic che-
motherapy; Lencioni 2016). The only outcome reported in the
trials was mortality at maximal follow-up. The trials did not report
the mean or median follow-up, but it appeared that the partici-
pants were followed up for 18 to 30months (Bruix 2012; Lencioni
2016). Thus, even the mortality at maximal follow-up appeared
to refer to medium-term mortality only. There was no evidence of
differences in mortality between the groups in any of the compar-
isons. None of the trials reported the proportion of people with
serious adverse events or number of serious adverse events, adverse
events (proportion), adverse events (number), quality of life, dis-
ease recurrence, or length of hospital stay. In one trial, more than
70% of people died during the follow-up period (Bruix 2012); in
another trial, approximately 50% of people died during the fol-
low-up period (Lencioni 2016). Therefore, the follow-up period
appears to be sufficiently long to detect any survival benefits of
the active intervention. However, the sample size was small in all
the comparisons and significant benefits or harms of intervention
could not be ruled out.
Overall completeness and applicability of
evidence
This review included only trial participants with intermediate-
stage hepatocellular carcinoma (i.e. BCLCB stage; i.e. large,multi-
nodular, Child-Pugh status A to B, and performance status 0).
Therefore, this review is applicable only to people with interme-
diate-stage hepatocellular carcinoma. It included a mixture of vi-
ral and non-viral aetiologies and people with cirrhotic and non-
cirrhotic livers. Hence, the review is applicable to viral or non-
viral aetiologies and people with cirrhotic and non-cirrhotic livers.
None of the trials reported the proportion of people with portal
hypertension. Therefore, it is not clear whether the findings of the
review are applicable in people with portal hypertension.
Quality of the evidence
The overall quality of the evidence was very low. All the trials were
at high risk of bias resulting in downgrading by one level. Since
therewas only one trial includedunder each comparison, it was not
possible to assess inconsistency. There was no issue of indirectness,
since mortality at maximal follow-up is a clinical outcome and
only direct comparisons were used. The sample size was small
(all comparisons downgraded by one level) and the confidence
intervals overlapped no effect and clinically significant effect for
all comparisons (downgraded by one level). Within-study risk of
bias and imprecision were the major reasons for downgrading the
quality of evidence. We did not explore publication bias because
of the too few trials included in this review.
Potential biases in the review process
The strengths of our review process are that we selected a range of
databases without any language restrictions. Three review authors
independently selected the trials and extracted the data, minimis-
ing the errors. We conducted the systematic review according to
the guidance provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We included only ran-
domised clinical trials as they provide the best estimates of inter-
vention effect.
The quality of evidence was very low. This is mainly because of
the sparse data. This is the major limitation of this review. The
BCLC classification is widely used in the Western hemisphere.
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However, a number of the excluded studies predated BCLC cri-
teria. Furthermore, BCLC is not used in the Eastern hemisphere,
where a number of the excluded trials originated from. As a result,
the majority of studies were excluded on the basis of not meet-
ing BCLC B criteria. Using an alternative classification for people
with the hepatocellular carcinoma, such as the CLIP or Okuda
classifications (Okuda 1985; CLIP 1998), might have resulted in
the inclusion of more trials in the analysis. However, this would
not have met our objectives.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in a
detailed manner. According to our choice of studies (i.e. only ran-
domised clinical trials), we might have missed a large number of
studies that address reporting of harms. Accordingly, this review is
biased towards benefits ignoring harms. We did not search for in-
terventions and trials registered at regulatory authorities (e.g., FDA
(US Food and Drug Administration); EMA (EuropeanMedicines
Agency), etc). This may have overlooked trials and as such trials
usually are unpublished, the lack of inclusion of such trials may
make our comparisons look more advantageous than they really
are.
Agreements and disagreements with other
studies or reviews
This is the first systematic review on this topic in people with inter-
mediate-stage hepatocellular carcinoma. We agreed with Lencioni
2016 that systemic therapy with sorafenib in addition to transar-
terial chemoembolisation did not offer any clinical benefit. We
disagreed with Bruix 2012 that systemic chemotherapy with so-
rafenib in addition to supportive treatment is beneficial in people
with intermediate-stage hepatocellular carcinoma.While there has
been no systematic review of the effect of sorafenib in people with
intermediate-stage hepatocellular carcinoma, one network meta-
analysis on advanced hepatocellular carcinoma showed that so-
rafenib may have survival benefit (Niu 2016).
We found no evidence from randomised clinical trials to support
the American Association for the Study of Liver Diseases recom-
mend TACE for people with intermediate-stage hepatocellular
carcinoma (Bruix 2011; EASL 2012). The possible reason for dis-
agreements is that we have used evidence from randomised clinical
trials only, which are generally considered the best quality of evi-
dence; non-randomised studies are likely to provide a biased esti-
mate of the effects in this situation as TACE is generally performed
only when there is sufficient remnant liver volume and when there
is no vascular spread (Lencioni 2013), and palliative treatment
alone is considered appropriate for people with insufficient rem-
nant liver volume or when there is vascular spread. Any differences
in survival or quality of life could be due to the extent of disease
rather than the intervention itself. Therefore, only evidence from
randomised clinical trials can provide a reasonable estimate of the
effects of TACE compared to symptomatic treatment only.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is no evidence from randomised clinical trials that
people with intermediate-stage hepatocellular carcinoma would
benefit from systemic chemotherapy with sorafenib either alone
or with transarterial chemoembolisation as a cointervention (very
low quality evidence).
Implications for research
We need high-quality randomised clinical trials designed to mea-
sure clinically important differences (e.g. all-cause mortality or
health-related quality of life) and following the SPIRIT (Standard
Protocol Items: Recommendations for Interventional Trials; Chan
2013b) and CONSORT guidelines (Schulz 2010). Future trials
on hepatocellular carcinoma should report the outcomes sepa-
rately by stage of hepatocellular carcinoma, so that it is possible
to determine whether interventions are beneficial in people with
intermediate-stage hepatocellular carcinoma.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bruix 2012
Methods Randomised clinical trial.
Participants Country: multi-centric, international.
Number randomised: 105.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 105.
Mean age: 69 years.
Females: 16 (15.2%).
Cirrhosis: not stated.
Portal hypertension: not stated.
Viral aetiology: 39 (37.1%).
Immunotherapy/antiviral adjuvant therapy: not stated.
Mean follow-up period (for all groups): not stated.
Criteria for intermediate-stage HCC and other inclusion criteria:
• Authors clearly stated BCLC stage B but no further details available in the
manuscript.
Interventions Participants were randomly assigned to 2 groups.
Group 1: sorafenib (n = 54).
Further details: chemotherapy: sorafenib 400 mg twice daily until radiological or symp-
tomatic progression
Group 2: placebo (n = 51).
Outcomes Mortality.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Study randomization was centralized, and assign-
ment to study groupswas conducted by computer to achieve
a balance between the two groups”
Allocation concealment (selection bias) Low risk Quote: “Study randomization was centralized, and assign-
ment to study groupswas conducted by computer to achieve
a balance between the two groups”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “phase 3, double-blind, placebo-controlled
trial…All eligible patients were randomly assigned in a 1:1
ratio to receive continuous oral treatment with either 400
mg of sorafenib (consisting of two 200-mg tablets) twice
daily or matching placebo”
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Bruix 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “phase 3, double-blind, placebo-controlled
trial…All eligible patients were randomly assigned in a 1:1
ratio to receive continuous oral treatment with either 400
mg of sorafenib (consisting of two 200-mg tablets) twice
daily or matching placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported.
For-profit bias High risk Quote: “The studywas designed by BayerHealthCare Phar-
maceuticals in conjunction with the principal academic in-
vestigators”
Other bias Low risk Comment: no other bias noted.
de Stefano 2015
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 18.
Post-randomisation dropouts: not stated.
Revised sample size: 18.
Mean age: not stated.
Females: not stated.
Cirrhosis: not stated.
Portal hypertension: not stated.
Viral aetiology: not stated.
Immunotherapy/antiviral adjuvant therapy: not stated.
Mean follow-up period (for all groups): not stated.
Criteria for intermediate-stage HCC and other inclusion criteria:
• Not stated but the authors clearly state BCLC stage B;
• People not eligible for TACE.
Interventions Participants were randomly assigned to 2 groups.
Group 1: sorafenib (n = not stated).
Further details: chemotherapy: sorafenib 400 mg twice daily until radiological or symp-
tomatic progression
Group 2: sorafenib plus RFA (n = not stated).
Further details: chemotherapy: sorafenib 400 mg twice daily until radiological or symp-
tomatic progression. RFA: details not stated in abstract
Outcomes None of the outcomes of interest to our review were reported
Notes
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de Stefano 2015 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Randomization will be performed with a list of a
priori sample prepared in sealed envelopes opaque”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “randomized open study”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “randomized open study”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: neither mortality nor morbidity was not re-
ported.
For-profit bias High risk Quote: “Financial support Bayer HealthCare, Onyx Phar-
maceuticals and Biocompatibles UK, Ltd”
Other bias Low risk Comment: no other bias noted.
Lencioni 2016
Methods Randomised clinical trial.
Participants Country: multi-centric, international.
Number randomised: 307.
Post-randomisation dropouts: not stated.
Revised sample size: 307.
Mean age: 64 years.
Females: 46 (15%).
Cirrhosis: 270 (87.9%).
Portal hypertension: not stated.
Viral aetiology: 197 (64.2%).
Immunotherapy/antiviral adjuvant therapy: not stated.
Average follow-up period in months (for all groups): not stated
Criteria for intermediate-stage HCC and other inclusion criteria:
• Unresectable, multi-nodular, without macrovascular involvement or extrahepatic
metastasis.
• Eastern Cooperative Oncology Group performance status 0.
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Lencioni 2016 (Continued)
• Child-Pugh A liver function.
• No previous local treatment.
Interventions Participants were randomly assigned to 2 groups.
Group 1: TACE plus sorafenib (n = 154).
Further details: TACE: drug-eluting beads containing doxorubicin 150 mg - multiple
cycles - duration not stated
Chemotherapy: sorafenib 400 mg twice daily in 4 week cycles - duration not stated
Group 2: TACE plus placebo (n = 153).
Further details: TACE: drug-eluting beads containing doxorubicin 150 mg - multiple
cycles - duration not stated
Outcomes Mortality.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “Randomization will be performed with a list of a
priori sample prepared in sealed envelopes opaque”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “phase II randomized, double-blind, placebo-con-
trolled study… Patients were randomized 1:1 to DEB-
TACE [doxorubicin-eluting bead transarterial chemoem-
bolization] (300-500 µm beads; 150 mg doxorubicin) plus
sorafenib (400 mg twice daily, continuously) or matching
placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “phase II randomized, double-blind, placebo-con-
trolled study… Patients were randomized 1:1 to DEB-
TACE (300-500 µm beads; 150 mg doxorubicin) plus so-
rafenib (400 mg twice daily, continuously) or matching
placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: morbidity was not reported.
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
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BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; RFA: radiofrequency ablation; TACE: transarterial chemoem-
bolisation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelaziz 2015 Not intermediate-stage HCC (people with performance status 0 or 1)
Anonymous 1995 Not intermediate-stage HCC (people with single tumour with BCLC A)
Arai 2010 Not intermediate-stage HCC (insufficient information in abstract to confirm BCLC stage)
Bartolozzi 1995 Variations in transarterial chemoembolisation.
Becker 2005 Not intermediate-stage HCC (people with portal vein thrombosis and Okuda stage III)
Bruix 1998 Not intermediate-stage HCC (people with single tumour and performance status > 1)
Chen 2002 Variations in transarterial chemoembolisation.
Chen 2007 Not a randomised clinical trial.
Cheng 2004 Not intermediate-stage HCC (people with single tumour with BCLC A)
Cheng 2008 Not intermediate-stage HCC (people with single tumour with BCLC A. Retracted in DeAngelis 2009).
Choi 2014 Not intermediate-stage HCC (people with BCLC C).
Chow 2002 Not intermediate-stage HCC (people with performance status 0 to 3 and Child-Pugh C)
DeAngelis 2009 Retraction of an excluded trial (Cheng 2008).
Doffoel 2008 Not intermediate-stage HCC (people with portal vein thrombosis and performance status > 2)
El-Kady 2013 Not intermediate-stage HCC (people with BCLC A.
Ferrari 2004 Not intermediate-stage HCC (people with single tumour with BCLC A)
Fischman 2014 Not intermediate-stage HCC (people with BCLC C).
Gallo 2006 Not intermediate-stage HCC (people with Child-Pugh C).
Gish 2009 Not intermediate-stage HCC (people with performance status 1)
Golfieri 2014 Variations in transarterial chemoembolisation.
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(Continued)
Hebbar 2015 Not intermediate-stage HCC (insufficient information in abstract to confirm BCLC stage)
Hilgard 2008 Not intermediate-stage HCC (people with performance status > 1)
Hou 2009 Not intermediate-stage HCC (people with T4 N0 M0 stage, extrahepatic invasion)
Huo 2003 Quasi-randomised study.
Iezzi 2013 Not a randomised clinical trial.
Inaba 2013 Not intermediate-stage HCC (people with performance status 0 to 2 and Child Pugh C)
Kolligs 2015 Not intermediate-stage HCC (people with BCLC C).
Kudo 2002 Not intermediate-stage HCC (people with BCLC A).
Kudo 2014 Not intermediate-stage HCC (people with BCLC C/D and performance status 1)
Lammer 2010 Not intermediate-stage HCC (people with performance status 1)
Li 2009 Not intermediate-stage HCC (people with single tumour).
Li 2010 Not intermediate-stage HCC (people with portal vein tumour thrombus)
Liu 2010 Variations in microwave ablation.
Livraghi 2005 Not intermediate-stage HCC (people with BCLC C).
Llovet 2002 Not intermediate-stage HCC (people with BCLC C).
Llovet 2007 Not intermediate-stage HCC (people with performance status 1 or 2)
Lo 2002 Not intermediate-stage HCC (people with portal vein thrombosis and performance status > 2)
Malagari 2010 Not intermediate-stage HCC (people with BCLC A).
Meyer 2016 Not intermediate-stage HCC (people with performance status 1)
Mohnike 2013 Not intermediate-stage HCC (people with BCLC C).
Morimoto 2010 Not intermediate-stage HCC (people with single tumours and performance status > 1)
Morimoto 2011 Not intermediate-stage HCC (people with single tumours and performance status > 1)
Okusaka 2012 Not intermediate-stage HCC (people with single tumour and performance status 0 to 2)
Padia 2013 Not a randomised clinical trial.
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Pelletier 1998 Not intermediate-stage HCC (people with Okuda III stage and therefore Child-Pugh C)
Sansonno 2012 Not intermediate-stage HCC (people with performance status 1)
Sarin 1994 Not intermediate-stage HCC (people withBCLC A).
Shi 2009 Variations in transarterial chemoembolisation.
Tanaka 2014 Not a randomised clinical trial.
Tang 2009 Not intermediate-stage HCC (people with portal vein tumour thrombus)
Ulbrich 2010a Not intermediate-stage HCC (people with BCLC A).
Ulbrich 2010b Not intermediate-stage HCC (people with BCLC A).
Wang 2007 Not intermediate-stage HCC (people with BCLC A).
Wang 2014 Not intermediate-stage HCC (people with BCLC C).
Wu 1995 Not intermediate-stage HCC (people with BCLC A).
Wu 1998 Not intermediate-stage HCC (people with Child-Pugh C).
Xie 2015 Not a randomised clinical trial.
Xu 2009 Not a randomised clinical trial.
Yang 2008 Not intermediate-stage HCC (people with Child-Pugh C).
Yin 2013 Not intermediate-stage HCC (people with BCLC A).
Zhang 2011 Not intermediate-stage HCC (people with recurrence after liver transplantation)
Zhou 2009 Not intermediate-stage HCC (people with portal vein thrombosis)
BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma.
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Characteristics of ongoing studies [ordered by study ID]
NCT02854839
Trial name or title NCT02854839.
Methods Randomised clinical trial.
Participants People with intermediate-stage hepatocellular carcinoma.
Interventions Intervention: MG4101.
Control: placebo.
Outcomes Overall survival, adverse events.
Starting date September 2016.
Contact information Kyung Gue Lee (kglee@greencross.com).
Notes
Seinstra 2012
Trial name or title TRACE.
Methods Randomised clinical trial.
Participants Barcelona Clinic Liver Cancer staging system intermediate stage
Interventions Transarterial radioembolisation versus transarterial chemoembolisation
Outcomes Overall survival, adverse events, quality of life, costs, cost effectiveness
Starting date Not stated, but the publication stated that they have already started including participants
Contact information Maurice AAJ van den Bosch (mbosch@umcutrecht.nl).
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Interventions for hepatocellular carcinoma
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 2 412 Hazard Ratio (Fixed, 95% CI) 0.85 [0.60, 1.18]
1.1 Chemotherapy versus no
chemotherapy
1 105 Hazard Ratio (Fixed, 95% CI) 0.72 [0.38, 1.37]
1.2 Transarterial
chemoembolisation with
systemic chemotherapy
versus transarterial
chemoembolisation without
systemic chemotherapy
1 307 Hazard Ratio (Fixed, 95% CI) 0.90 [0.61, 1.33]
Analysis 1.1. Comparison 1 Interventions for hepatocellular carcinoma, Outcome 1 Mortality at maximal
follow-up.
Review: Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis
Comparison: 1 Interventions for hepatocellular carcinoma
Outcome: 1 Mortality at maximal follow-up
Study or subgroup Chemotherapy No chemotherapy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chemotherapy versus no chemotherapy
Bruix 2012 54 -0.32850407 (0.32900286) 51 27.1 % 0.72 [ 0.38, 1.37 ]
Subtotal (95% CI) 54 51 27.1 % 0.72 [ 0.38, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
2 Transarterial chemoembolisation with systemic chemotherapy versus transarterial chemoembolisation without systemic chemotherapy
Lencioni 2016 154 -0.10758521 (0.20052772) 153 72.9 % 0.90 [ 0.61, 1.33 ]
Subtotal (95% CI) 154 153 72.9 % 0.90 [ 0.61, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 208 204 100.0 % 0.85 [ 0.60, 1.18 ]
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours chemotherapy Favours no chemotherapy
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A P P E N D I C E S
Appendix 1. Barcelona Clinic Liver Cancer (BCLC) staging classification
Stage 0: very early-stage hepatocellular carcinoma (single tumour less than 2 cm).
Stage A: early-stage hepatocellular carcinoma (single tumour or three tumours less than 3 cm in maximum diameter).
Stage B: intermediate-stage hepatocellular carcinoma (large multiple tumours).
Stage C: advanced-stage hepatocellular carcinoma (vascular invasion or extrahepatic spread or restriction in activities).
Stage D: end-stage hepatocellular carcinoma (poor performance status or Child-Pugh C liver functional status (based on bilirubin levels,
albumin levels, prothrombin time or international normalised ratio (INR), presence of ascites, and presence hepatic encephalopathy).
Simplified from sources: Llovet 1999; Llovet 2003.
Appendix 2. Milan criteria
1. Single lesion less than 5 cm in diameter.
2. Two or three lesions less than 3 cm in maximum diameter.
3. No preoperative evidence or suspicion of invasion of blood vessels or lymph nodes by tumour.
4. No preoperative evidence of extrahepatic metastases.
People meet the Milan criteria if they meet either criteria numbers 1, 3, and 4 or criteria numbers 2, 3, and 4.
Simplified from source: Mazzaferro 1996.
Appendix 3. Methods for network meta-analysis if we find this is possible in the future
Measures of treatment effect
Relative treatment effects
For dichotomous variables (e.g. proportion of participants with serious adverse events or any adverse events), we will calculate the odds
ratio with 95% credible interval (or Bayesian confidence interval) (Severini 1993). For continuous variables (e.g. quality of life reported
on the same scale), we will calculate the mean difference with 95% credible interval. We will use standardised mean difference values
with 95% credible interval for quality of life if included trials use different scales. For count outcomes (e.g. number of adverse events
and serious adverse events), we will calculate the rate ratio with 95% credible interval. For time-to-event data (e.g. mortality at maximal
follow-up), we will calculate hazard ratio with 95% credible interval.
Relative ranking
We will estimate the ranking probabilities for all treatments of being at each possible rank for each intervention. Then, we will obtain
the surface under the cumulative ranking curve (SUCRA) (cumulative probability) and rankogram (Salanti 2011; Chaimani 2013).
Unit of analysis issues
We will collect data for all trial treatment groups that meet the inclusion criteria. The codes for analysis, that we will use, accounts for
the correlation between the effect sizes from from trials with more than two groups.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. We
will assess the presence of clinical heterogeneity by comparing effect estimates under different categories of potential effect modifiers.
Different study designs and risk of bias may contribute to methodological heterogeneity.
We will assess the statistical heterogeneity by comparing the results of the fixed-effect model meta-analysis and the random-effects
model meta-analysis, between-study standard deviation (tau2 and comparing this with values reported in the study of the distribution
of between-study heterogeneity (Turner 2012)), and by calculating I2 (using Stata/SE 14.2). If we identify substantial heterogeneity,
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clinical, methodological, or statistical, we will explore and address heterogeneity in a subgroup analysis (see ‘Subgroup analysis and
investigation of heterogeneity for network meta-analysis’ section).
Assessment of transitivity across treatment comparisons
We will evaluate the plausibility of transitivity assumption (the assumption that the participants included in the different studies with
different immunosuppressive regimens can be considered to be a part of a multi-arm randomised clinical trial and could potentially
have been randomised to any of the treatments) (Salanti 2012). In other words, any participant that meets the inclusion criteria is, in
principle, equally likely to be randomised to any of the above eligible interventions. If there is any concern that the clinical safety and
effectiveness are dependent upon the effect modifiers, we will continue to do traditional Cochrane pair-wise comparisons and we will
not perform a network meta-analysis on all participant subgroups.
Assessment of reporting biases
For the network meta-analysis, we will judge the reporting bias by the completeness of the search (i.e. searching various databases and
including conference abstracts), as we do not currently find any meaningful order to perform a comparison-adjusted funnel plot as
suggested by Chaimani 2012. However, if we find any meaningful order, for example, the control group used depended upon the year
of conduct of the trial, we will use comparison-adjusted funnel plot as suggested by Chaimani 2012.
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple interventions simultaneously for each of the primary and secondary
outcomes. Network meta-analysis combines direct evidence within trials and indirect evidence across trials (Mills 2012).We will obtain
a network plot to ensure that the trials were connected by treatments using Stata/SE 14.2 (Chaimani 2013). We will exclude any trials
that were not connected to the network. We will conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo
method in OpenBUGS 3.2.3 as per the guidance from the National Institute for Health and Care Excellence (NICE) Decision Support
Unit (DSU) documents (Dias 2014a). We will model the treatment contrast (i.e. log odds ratio for binary outcomes, mean difference
or standardised mean difference for continuous outcomes, log rate ratio for count outcomes, and log hazard ratio for time-to-event
outcomes) for any two interventions (’functional parameters’) as a function of comparisons between each individual intervention and
an arbitrarily selected reference group (’basic parameters’) (Lu 2006) using appropriate likelihood functions and links. We will use
binomial likelihood and logit link for binary outcomes, Poisson likelihood and log link for count outcomes, binomial likelihood and
complementary log-log link for time-to-event outcomes, and normal likelihood and identity link for continuous outcomes. We will
perform a fixed-effect model and random-effects model for the network meta-analysis. We will report both models for comparison with
the reference group in a forest plot. For pairwise comparison, we will report the fixed-effect model if the two models reported similar
results; otherwise, we will report the more conservative model.
We will use a hierarchical Bayesian model using three different initial values using codes provided by NICE DSU (Dias 2014a). We will
use a normal distribution with large variance (10,000) for treatment effect priors (vague or flat priors). For the random-effects model,
we will use a prior distributed uniformly (limits: 0 to 5) for between-trial standard deviation but assumed similar between-trial standard
deviation across treatment comparisons (Dias 2014a). We will use a ’burn-in’ of 5000 simulations, check for convergence visually,
and run the models for another 10,000 simulations to obtain effect estimates. If we did not obtain convergence, we will increase the
number of simulations for ’burn-in’. If we do not obtain convergence still, we will use alternate initial values and priors using methods
suggested by van Valkenhoef 2012. We will also estimate the probability that each intervention ranks at one of the possible positions
using the NICE DSU codes (Dias 2014a).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of the violation of transitivity assumption) by fitting both an inconsistency model and
a consistency model. We will use the inconsistency models used in the NICEDSUmanual, as we plan to use a common between-study
deviation for the comparisons (Dias 2014b). In addition, we will use the design-by-treatment full interaction model (Higgins 2012)
and IF (inconsistency factor) plots (Chaimani 2013) to assess inconsistency. In the presence of inconsistency, we will assess whether the
inconsistency is because of clinical or methodological heterogeneity by performing separate analyses for each of the different subgroups
mentioned in the ‘Subgroup analysis and investigation of heterogeneity for network meta-analysis’ section below.
If there is evidence of inconsistency, we will identify areas in the network where substantial inconsistency might be present in terms of
clinical and methodological diversities between trials and, when appropriate, limit network meta-analysis to a more compatible subset
of trials.
Direct comparison
We will perform the direct comparisons using the same codes and the same technical details.
Sample size calculations
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To control for the risk of random errors, we will interpret the information with caution when the accrued sample size in the network
meta-analysis (i.e. across all treatment comparisons) was less than the required sample size (required information size). For calculation
of the required information size, see Appendix 5.
Subgroup analysis and investigation of heterogeneity for network meta-analysis
Wewill assess the differences in the effect estimates between the subgroups listed in Subgroup analysis and investigation of heterogeneity
using meta-regression with the help of the OpenBUGS code (Dias 2012a) if we include a sufficient number of trials. We will use the
potential modifiers as study level co-variates for meta-regression. We will calculate a single common interaction term (Dias 2012a). If
the 95% credible intervals of the interaction term do not overlap zero, we will consider this as evidence of difference in subgroups.
Presentation of results
We will present the effect estimates with 95% CrI for each pairwise comparisons calculated from the direct comparisons and network
meta-analysis. We will also present the cumulative probability of the treatment ranks (i.e. the probability that the treatment is within
the top two, the probability that the treatment is within the top three, etc.) in graphs (surface under the cumulative ranking curve or
SUCRA) (Salanti 2011). We will also plot the probability that each treatment is best, second best, third best etc for each of the different
outcomes (rankograms), which are generally considered more informative (Salanti 2011; Dias 2012b).
We will present the ’Summary of findings’ tables for mortality. In the ’Summary of findings for the main comparison’, we will follow
the approach suggested by Puhan et al. (Puhan 2014). First, we will calculate the direct and indirect effect estimates and 95% credible
intervals using the node-splitting approach (Dias 2010), i.e. calculate the direct estimate for each comparison by including only trials
in which there was direct comparison of treatments and the indirect estimate for each comparison by excluding the trials in which
there was direct comparison of treatments. Then we will rate the quality of direct and indirect effect estimates using GRADE which
takes into account the risk of bias, inconsistency, directness of evidence, imprecision, and publication bias (Guyatt 2011). Then, we
will present the estimates of the network meta-analysis and rate the quality of network meta-analysis effect estimates as the best quality
of evidence between the direct and indirect estimates (Puhan 2014). In addition, in the same table, we will present illustrations and
information on the number of trials and participants as per the standard ’Summary of Findings’ Table.
Appendix 4. Search strategies
Database Time span Search strategy
The Central Register of Controlled Trials
(CENTRAL)
Issue 8, 2016. #1MeSH descriptor: [Carcinoma, Hepatocellular]
explode all trees
#2 (((hepat* or liver) and carcinoma*) or hepato-
cellular caricoma or hepatocarcinoma or hepatoma
or HCC or “primary liver cancer”)
#3 #1 or #2
#4 (intermediate or large or multinodular)
#5 #3 and #4
MEDLINE (OvidSP) January 1947 to September 2016. 1. exp Carcinoma, Hepatocellular/
2. (((hepat* or liver) and carcinoma*) or hepato-
cellular caricoma or hepatocarcinoma or hepatoma
or HCC or “primary liver cancer”).ti,ab
3. 1 or 2
4. (intermediate or large or multinodular).ti,ab.
5. 3 and 4
6. randomized controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized.ab.
9. placebo.ab.
10. drug therapy.fs.
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(Continued)
11. randomly.ab.
12. trial.ab.
13. groups.ab.
14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp animals/ not humans.sh.
16. 14 not 15
17. 5 and 16
Embase (OvidSP) January 1974 to September 2016. 1. exp liver cell carcinoma/
2. (((hepat* or liver) and carcinoma*) or hepato-
cellular caricoma or hepatocarcinoma or hepatoma
or HCC or “primary liver cancer”).ti,ab
3. 1 or 2
4. (intermediate or large or multinodular).ti,ab.
5. 3 and 4
6. exp crossover-procedure/ or exp double-blind
procedure/ or exp randomized controlled trial/ or
single-blind procedure/
7. (((((random* or factorial* or crossover* or cross
over* or cross-over* or placebo* or double*) adj
blind*) or single*) adj blind*) or assign* or allocat*
or volunteer*).af
8. 6 or 7
9. 5 and 8
Science Citation Index Expanded (Web of
Knowledge)
January 1945 to September 2016. #1 TS=(((hepat* or liver) and carcinoma*) or hep-
atocellular caricoma or hepatocarcinoma or hep-
atoma or HCC or “primary liver cancer”)
#2 TS=(intermediate or large or multinodular)
#3 TS=(random* OR rct* OR crossover OR
maskedOR blind* OR placebo* ORmeta-analysis
OR systematic review* OR meta-analys*)
#4 #1 AND #2 AND #3
World Health Organization International
Clini-
cal Trials Registry Platform Search Portal (
apps.who.int/trialsearch/Default.aspx)
September 2016. Title: (intermediate or large or multinodular)
Condition: “hepatocellular carcinoma” or “primary
liver cancer” or “liver cell cancer” or hepatoma
ClinicalTrials.gov September 2016. intermediate OR large OR multinodular | Inter-
ventional Studies | “hepatocellular carcinoma” OR
“primary liver cancer” OR “liver cell cancer” OR
hepatoma | Phase 2, 3, 4
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Appendix 5. Sample size calculation
On average, 75% of people with intermediate-stage hepatocellular carcinoma are alive at 24 months (Bruix 1998). The required
information size based on a control group proportion of 75%, a relative risk reduction of 20% in the intervention group, type I error of
5%, and type II error of 50% is 304 participants. Network analyses are more prone to the risk of random errors than direct comparisons
(Del Re 2013). Accordingly, a greater sample size is required in indirect comparisons than direct comparisons (Thorlund 2012). The
power and precision in indirect comparisons depends upon various factors, such as the number of participants included under each
comparison and the heterogeneity between the trials (Thorlund 2012). If there is no heterogeneity across the trials, the sample size in
indirect comparisons would be equivalent to the sample size in direct comparisons. The effective indirect sample size can be calculated
using the number of participants included in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants
in the direct comparison A versus C (nAC ) and a sample size of 7500 participants in the direct comparison B versus C (nBC) results in
an effective indirect sample size of 1876 participants. However, in the presence of heterogeneity within the comparisons, the sample
size required is higher. In the above scenario, for an I2 statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2)
of 25%, the effective indirect sample size is 1407 participants. For an I2 statistic for each of the comparisons A versus C and B versus
C of 50%, the effective indirect sample size is 938 participants (Thorlund 2012). If there were only three groups and the sample size
in the trials is more than the required information size, we planned to calculate the effective indirect sample size using the following
generic formula (Thorlund 2012):
((nAC x (1 - IAC
2)) x (nBC x (1 - IBC
2))/((nAC x (1 - IAC
2)) + (nBC x (1 - IBC
2)).
There is currently no method to calculate the effective indirect sample size for a network analysis involving more than three intervention
groups.
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S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• There was only one comparison. So we did not perform the network meta-analysis, and assessed the comparative benefits and
harms of different interventions using standard Cochrane methodology. The methodology that we plan to use if we conduct a
network meta-analysis in future is available in Appendix 3.
• We performed Trial Sequential Analysis in addition to conventional method of assessing the risk of random errors using P-value.
N O T E S
Considerable overlap is evident in the ’Methods’ sections of this review and those of several other reviews written by the same group of
authors.
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